Business and Finance

Acquisition is expected to offer life sciences clients a boost in expertise and insight.

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

MoU aims to align the pharmaceutical and cold chain sectors by boosting operations.

Pfizer said that the addition of Seagen to its current operations could add more than $10 billion in risk-adjusted revenues by 2030.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The designation—which ranks the fastest-growing companies in North America—is powered by AeroSafe’s 477% growth rate.

Purchase grows the company’s CRYOPDP domestic footprint while strengthening working relationship between both parties.

Parties will provide processing and packaging machinery services.

Stem Cell Reports takes a look at DTC online advertising claims that these are ‘immune boosters.’

Bayer said it will explore access options for patients with follicular lymphoma currently receiving Aliqopa who have experienced a favorable response to treatment.

Blue Fin Group exec speaks on his upcoming feature.

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Blue Fin Group executive highlights how leaders can plan for immediate profitable lifecycles and beyond.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Session explains how to use this information to help bolster market intelligence, market access, and affordability strategies.

Conference presentation explores groundbreaking topics impacting the pharma industry.

Session explores how on-market products have done, and what to expect from new biosimilars.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

New company to be publicly listed as Citius Oncology, Inc.

Investment offers opportunity to expand global footprint, company says.

Sector is anticipated to grow at a CAGR of 9.3%.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

Acquisition helps expand pharma marketing reach and opens door for growth opportunities.

The conference will focus on the full breadth of commercialization strategies and operations.

Acquisition includes company’s inflammatory disease medicines.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.